PDCD1 and cancer: Monoclonal antibodies against PD-1 (programmed cell death protein-1) and PD-L1 (programmed death-ligand 1) have changed the treatment landscape of metastatic non-small cell lung cancer (mNSCLC), which remains the number one cause of cancer-related mortality in both men and women1.